Paper Details

  1. Home
  2. Paper Details

Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma.

Author: AllisonDebbie E, BoyterAnne C, EvansDavid J W, KewKayleigh M

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Uncontrolled asthma puts a strain on healthcare, leading to frequent hospital visits and additional medication. While long-acting beta2-agonists (LABAs) are commonly added to inhaled corticosteroids (ICS) for those with uncontrolled asthma, they have safety concerns. Long-acting muscarinic antagonists (LAMAs) are now being considered as a potential alternative for those with asthma who don't respond well to ICS alone.
Paper Details　
Original Abstract of the Article :
Poorly controlled asthma and preventable exacerbations place a significant strain on healthcare, often requiring additional medications, hospital stays or treatment in the emergency department.Long-acting beta2-agonists (LABA) are the preferred add-on treatment for adults with asthma whose symptoms ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6513433/

データ提供：米国国立医学図書館（NLM）

Long-Acting Muscarinic Antagonists (LAMA): A New Frontier in Asthma Management

Asthma, a chronic respiratory condition affecting millions, can significantly impact a person's quality of life. This article delves into the world of asthma management, exploring the potential of long-acting muscarinic antagonists (LAMA) as an alternative add-on therapy for poorly controlled asthma. The article discusses the rationale for using LAMA as an alternative to long-acting beta2-agonists (LABA), which have been the preferred add-on treatment but come with safety concerns.

LAMA: A Breath of Fresh Air for Asthma Management

The article highlights the potential of LAMA as a novel approach to managing asthma. The researchers emphasize the growing body of evidence supporting the efficacy of LAMA in chronic obstructive pulmonary disease (COPD) and their potential as a safe and effective alternative to LABA for individuals with uncontrolled asthma.

Navigating the Desert of Asthma: Exploring New Options

The desert of asthma can be a challenging landscape, requiring careful navigation to manage symptoms and prevent exacerbations. This article offers a new perspective on asthma management, highlighting the potential benefits of LAMA as an alternative to LABA. The article encourages further research to solidify the role of LAMA in asthma treatment and to develop personalized treatment plans that address the individual needs of patients.

Dr.Camel's Conclusion

This article reminds us that the search for effective asthma treatments is an ongoing journey. The emergence of LAMA as a potential alternative to LABA offers a promising new direction in asthma management. This article underscores the importance of exploring innovative therapies and personalized treatment approaches to improve the lives of individuals living with asthma.

Date :
  1. Date Completed 2016-02-10
  2. Date Revised 2023-03-03
Further Info :

Pubmed ID

26031392

DOI: Digital Object Identifier

PMC6513433

Related Literature

Article Analysis
・Effective treatment of asthma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.